Key result
The atorvastatin-fenofibrate combination reduced LDL cholesterol by 46% and triglycerides by 50%, and increased HDL cholesterol by 22%, more than either monotherapy.
Why the study?
Does the combination of atorvastatin and fenofibrate improve lipid profiles compared to either drug alone in patients with type 2 diabetes and combined hyperlipidemia?
RCT (n=120)
randomly assigned
Does the combination of atorvastatin and fenofibrate improve lipid profiles compared to either drug alone in patients with type 2 diabetes and combined hyperlipidemia?
Combination therapy with atorvastatin and fenofibrate is highly effective at improving lipid profiles and reducing estimated CAD risk in patients with type 2 diabetes and combined hyperlipidemia compared to monotherapy.
Answers are grounded in this paper and cite their sources.
Combination may improve lipids vs monotherapy in T2DM with CHL; leaves open CAD outcome benefits.
OBJECTIVE: This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia (CHL). RESEARCH DESIGN AND METHODS: A total of 120 consecutive patients, who were free of coronary artery disease (CAD) at entry, were studied for a period of 24 weeks. These patients were randomly assigned to atorvastatin (20 mg/day, n = 40), micronized fenofibrate (200 mg/day, n = 40), or a combination of both (atorvastatin 20 mg/day plus fenofibrate 200 mg/day, n = 40). The effect of treatment on LDL cholesterol, triglycerides (TGs), HDL cholesterol, apolipoprotein A-I and B, lipoprotein(a), and plasma fibrinogen (PF) was recorded. Moreover, the percentage of patients that reached the American Diabetes Association treatment goals and the estimated CAD risk status were calculated. RESULTS: No patient was withdrawn from the study because of side effects. The atorvastatin-fenofibrate combination reduced total cholesterol by 37%, LDL cholesterol by 46%, TGs by 50%, and PF by 20%, whereas it increased HDL cholesterol by 22% (P < 0.0001 for all). These changes were significantly better than those of both monotherapies. Of the patients on drug combination, 97.5% reached the LDL cholesterol treatment goal of <100 mg/dl, 100% reached the desirable TG levels of <200 mg/dl, and 60% reached the optimal HDL cholesterol levels of >45 mg/dl. These rates were significantly higher than those of both monotherapies. Combined treatment reduced the 10-year probability for myocardial infarction from 21.6 to 4.2%. CONCLUSIONS: The atorvastatin-fenofibrate combination has a highly beneficial effect on all lipid parameters and PF in patients with type 2 diabetes and CHL. It improved patients' CAD risk status significantly more than each drug alone.
No takes yet. Share an insight, caveat, or question.
Athyros et al. (2002) conducted an RCT in Type 2 diabetes with combined hyperlipidemia (n=120). Atorvastatin-fenofibrate combination vs. Atorvastatin 20 mg/day or micronized fenofibrate 200 mg/day alone was evaluated on Changes in lipid profile (total cholesterol, LDL cholesterol, triglycerides, HDL cholesterol, and plasma fibrinogen) (p=<0.0001). The atorvastatin-fenofibrate combination reduced LDL cholesterol by 46% and triglycerides by 50%, and increased HDL cholesterol by 22%, more than either monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: